We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$833M
AUM Growth
-$400M
Cap. Flow
-$240M
Cap. Flow %
-28.81%
Top 10 Hldgs %
56.65%
Holding
156
New
48
Increased
29
Reduced
27
Closed
47

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25M
2
CELG
Celgene Corp
CELG
+$22.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.2M
4
MGNX icon
MacroGenics
MGNX
+$18.8M
5
MNKD icon
MannKind Corp
MNKD
+$17.8M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$144M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$69.5M
3
GILD icon
Gilead Sciences
GILD
+$56.7M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$26.6M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 85.14%
2 Miscellaneous 12.73%
3 Consumer Staples 2.06%
4 Consumer Discretionary 0.05%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
101
Axogen
AXGN
$2.42B
$20K ﹤0.01%
4,500
– –
IMMU
102
DELISTED
Immunomedics Inc
IMMU
$13K ﹤0.01%
2,853
-734,652
-100% -$3.27M
STML
103
DELISTED
Stemline Therapeutics, Inc.
STML
$1K ﹤0.01%
38
-90,170
-100% -$2.41M
ABUS icon
104
Arbutus Biopharma
ABUS
$1B
– –
-159,309
Closed -$1.11M
ACAD icon
105
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-610,615
Closed -$16.8M
AMGN icon
106
Amgen
AMGN
$203B
– –
-91,675
Closed -$10.3M
AMRN
107
CALL
Amarin Corp
AMRN
$294M
– –
-7,240
Closed -$915K
AMRN
108
PUT
Amarin Corp
AMRN
$294M
– –
-43,425
Closed -$5.49M
ANIK icon
109
Anika Therapeutics
ANIK
$280M
– –
-144,067
Closed -$3.44M
CLDX icon
110
CALL
Celldex Therapeutics
CLDX
$3.02B
– –
-3,220
Closed -$1.71M
CYH icon
111
Community Health Systems
CYH
$419M
– –
-4,132
Closed -$142K
EHC icon
112
Encompass Health
EHC
$12B
– –
-5,267
Closed -$144K
EYPT icon
113
EyePoint Inc
EYPT
$316M
– –
-77,200
Closed -$3.17M
FBIO icon
114
PUT
Fortress Biotech
FBIO
$83M
– –
-33,460
Closed -$3.52M
IBB icon
115
PUT
iShares Biotechnology ETF
IBB
$10.3B
– –
-434,400
Closed -$30.4M
IONS icon
116
Ionis Pharmaceuticals
IONS
$7.85B
– –
-192,800
Closed -$7.24M
IWM icon
117
PUT
iShares Russell 2000 ETF
IWM
$76.9B
– –
-96,500
Closed -$10.3M
MD icon
118
Pediatrix Medical
MD
$2.17B
– –
-2,750
Closed -$138K
MDGL icon
119
Madrigal Pharmaceuticals
MDGL
$12.1B
– –
-68,035
Closed -$15M
MOH icon
120
Molina Healthcare
MOH
$10.8B
– –
-3,590
Closed -$128K
MYGN icon
121
CALL
Myriad Genetics
MYGN
$371M
– –
-58,300
Closed -$1.37M
NBIX icon
122
PUT
Neurocrine Biosciences
NBIX
$15.2B
– –
-289,500
Closed -$3.28M
PCRX icon
123
Pacira BioSciences
PCRX
$960M
– –
-272,034
Closed -$13.1M
SGMO
124
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-965,000
Closed -$10.1M
VNDA icon
125
CALL
Vanda Pharmaceuticals
VNDA
$302M
– –
-482,600
Closed -$5.28M
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2013 Portfolio in Review

As of Q4 2013, Perceptive Advisors held 156 positions worth $833M, down 32% from $1.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Perceptive Advisors withdrew a net $240M in Q4 2013, closing 47 positions and reducing 27 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $69.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in MacroGenics worth $19.7M.

  • Perceptive Advisors's largest Q4 2013 buy was MacroGenics: 717,705 shares worth $19.7M.
  • Perceptive Advisors added most to Vertex Pharmaceuticals in Q4 2013, an estimated $25M increase.
  • Perceptive Advisors's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $144M.
  • Perceptive Advisors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $69.5M.
  • Perceptive Advisors's ten largest holdings make up 57% of its $833M portfolio in Q4 2013.
  • Perceptive Advisors opened 48 new positions and closed 47 in Q4 2013.
  • Perceptive Advisors's portfolio value fell 32% quarter-over-quarter to $833M.

Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.